Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways to Participate in Stifel Virtual CNS Forum

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

About Compass Pathways

COMPASS Pathways Plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing.

Enquiries

Media: Media, media@compasspathways.com
Investors: Stephen Schultz, stephen.schultz@compasspathways.com , +1 401 290 7324

News Provided by Business Wire via QuoteMedia

CMPS
The Conversation (0)
COMPASS Pathways Plc

COMPASS Pathways Plc

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Burley Minerals

Exploration License Granted over Cane Bore Iron Project

Burley Minerals Limited (ASX: BUR, “Burley” or “the Company”) is pleased to announce that Exploration License E08/3424 (the Cane Bore Iron Project) was granted by The Department of Energy, Mines, Industry Regulation and Safety (DEMIRS). Cane Bore is located within the world class Pilbara Province of the Western Australia and located less than 100 km by sealed road from the export Port of Onslow.

Keep reading...Show less
Aclara Announces the Closing of the Transaction with Cap and the Receipt of Initial Payment of Us$9.7M as Part of the US$29.1M Strategic Investment

Aclara Announces the Closing of the Transaction with Cap and the Receipt of Initial Payment of Us$9.7M as Part of the US$29.1M Strategic Investment

Aclara Resources Inc. ("Aclara" or the "Company") (TSX:ARA) is pleased to announce the closing of the acquisition by CAP S.A. ("CAP") of its 20% equity ownership interest in REE Uno SpA ("REE Uno"), the Company's Chilean subsidiary that owns the Penco Module project, and receipt by the Company of the initial payment of approximately US$9.7 million in connection with such acquisition. The acquisition is made pursuant to the terms of the previously announced investment agreement entered into between CAP and Aclara on March 13, 2024 (the "Investment Agreement"). Under the terms of the Investment Agreement, payments are to be made in three tranches, of which the remaining two tranches in the amounts of US$12.5 million and US$6.9 million are to be made in January of 2025 and 2026, respectively

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Burley Minerals

Burley’s Pilbara Iron Ore Assets Advancing

Burley Minerals Limited (ASX: BUR, “Burley” or “the Company”) advises that a heritage protection agreement has been signed with Yindjibarndi Aboriginal Corporation over the Broad Flat Well exploration license area. Heritage surveys are planned for late-April/early-May 2024.

Keep reading...Show less
Northern Dynasty: U.S. Army Corps Remand Highlights Serious Flaws in the Permitting Decision

Northern Dynasty: U.S. Army Corps Remand Highlights Serious Flaws in the Permitting Decision

Northern Dynasty Minerals Ltd. (TSX:NDM)(NYSE American:NAK) ("Northern Dynasty" or the "Company" or "NDM") announces that the April 25, 2023 action by the U.S. Army Corps of Engineers ("USACE") Pacific Ocean Division to remand the permit decision back to the USACE - Alaska District ("the District") is a strong win for the Pebble Project

"We have been saying that the record of decision ("ROD") process was not fairly conducted since 2020 and are pleased to see that the Review Officer has raised similar concerns on many substantive issues," said Ron Thiessen, President and CEO of Northern Dynasty. "The two major areas for the negative ROD decision, namely the deemed non-compliance of our comprehensive mitigation plan ("CMP") and the Public Interest Review ("PIR"), were highlighted by the Review Officer as areas where the District did not carry out the proper process in arriving at its decision. This remand decision is a ‘strong win' for the project because it brings these issues to light and directs the District to address them, potentially setting the stage for a much different outcome."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Lithium Power International

LPI Commences Drilling At Greenbushes Lithium Project

Lithium Power International Limited (ASX: LPI) (“LPI” or the “Company”) is pleased to announce that the Company this week commenced a drilling program at its East Kirup lithium prospect, part of the Company’s Greenbushes Project in the south-west of Western Australia.
Keep reading...Show less
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroup
  • Findings published in the March edition of the Journal of Clinical Psychiatry

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45 th Annual Health Care Conference at 1:10 pm ET on March 3 rd , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×